The Josep Carreras Leukaemia Research Institute (IJC) welcomed the 2025 edition of its annual Preceptorship course on 6-7 November, bringing together European haematology physicians and biologists to explore the latest advances in Acute Lymphoblastic Leukaemia (ALL). Organised by Dr Josep-Maria Ribera, Group Leader of IJC’s ALL research group, and Dr Anna Torrent, haematology physician at the Catalan Institute of Oncology (ICO), with support from Incyte, the course provides an intensive forum for sharing the most up-to-date knowledge on the biology, diagnosis, and treatment of this complex disease.

This year’s programme attracted participants from Germany, Belgium, Croatia, Slovenia, Luxembourg, North Macedonia, Romania and Spain. The course was structured into three sections: genetic studies and residual disease in ALL, standard treatment in children and adults, and new therapies, including immunotherapy, targeted therapy and cell therapy. It also included a section dedicated to the presentation of clinical cases of particular interest.

Dr Ribera emphasised the importance of continuing professional training in this rapidly evolving field: “As our understanding of ALL biology deepens, we are able to develop more precise and personalised therapies. It is crucial to share this knowledge through professional training, so that the next generation of haematologists can effectively apply these advances in clinical practice.” The Preceptorship not only updates participants on the latest scientific and clinical developments but also strengthens collaboration among Europe’s leading ALL specialists. Dr Ribera thanked his ALL team for their work and the Josep Carreras Institute and the Catalan Institute of Oncology for their ongoing support in delivering the course.